NVCR vs. MRK
Compare and contrast key facts about NovoCure Limited (NVCR) and Merck & Co., Inc. (MRK).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NVCR or MRK.
Correlation
The correlation between NVCR and MRK is 0.35, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
NVCR vs. MRK - Performance Comparison
Loading data...
Key characteristics
NVCR:
0.10
MRK:
-1.52
NVCR:
0.95
MRK:
-2.13
NVCR:
1.11
MRK:
0.72
NVCR:
0.13
MRK:
-0.96
NVCR:
0.40
MRK:
-1.76
NVCR:
29.90%
MRK:
22.68%
NVCR:
81.54%
MRK:
26.31%
NVCR:
-95.07%
MRK:
-68.62%
NVCR:
-92.30%
MRK:
-41.52%
Fundamentals
NVCR:
$1.94B
MRK:
$194.98B
NVCR:
-$1.51
MRK:
$6.88
NVCR:
-0.47
MRK:
0.71
NVCR:
3.13
MRK:
3.05
NVCR:
5.35
MRK:
4.03
NVCR:
$621.71M
MRK:
$63.92B
NVCR:
$479.70M
MRK:
$51.75B
NVCR:
-$105.45M
MRK:
$27.30B
Returns By Period
In the year-to-date period, NVCR achieves a -41.68% return, which is significantly lower than MRK's -22.97% return.
NVCR
-41.68%
8.08%
-0.34%
5.53%
-23.18%
N/A
MRK
-22.97%
-2.04%
-24.95%
-39.86%
3.58%
6.22%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
NVCR vs. MRK — Risk-Adjusted Performance Rank
NVCR
MRK
NVCR vs. MRK - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for NovoCure Limited (NVCR) and Merck & Co., Inc. (MRK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
NVCR vs. MRK - Dividend Comparison
NVCR has not paid dividends to shareholders, while MRK's dividend yield for the trailing twelve months is around 4.16%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVCR NovoCure Limited | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
MRK Merck & Co., Inc. | 4.16% | 3.14% | 2.72% | 2.52% | 3.41% | 3.03% | 2.48% | 2.60% | 3.36% | 3.14% | 3.43% | 3.12% |
Drawdowns
NVCR vs. MRK - Drawdown Comparison
The maximum NVCR drawdown since its inception was -95.07%, which is greater than MRK's maximum drawdown of -68.62%. Use the drawdown chart below to compare losses from any high point for NVCR and MRK. For additional features, visit the drawdowns tool.
Loading data...
Volatility
NVCR vs. MRK - Volatility Comparison
NovoCure Limited (NVCR) has a higher volatility of 16.62% compared to Merck & Co., Inc. (MRK) at 10.21%. This indicates that NVCR's price experiences larger fluctuations and is considered to be riskier than MRK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
NVCR vs. MRK - Financials Comparison
This section allows you to compare key financial metrics between NovoCure Limited and Merck & Co., Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NVCR vs. MRK - Profitability Comparison
NVCR - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, NovoCure Limited reported a gross profit of 116.47M and revenue of 154.99M. Therefore, the gross margin over that period was 75.2%.
MRK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Merck & Co., Inc. reported a gross profit of 12.11B and revenue of 15.53B. Therefore, the gross margin over that period was 78.0%.
NVCR - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, NovoCure Limited reported an operating income of -37.87M and revenue of 154.99M, resulting in an operating margin of -24.4%.
MRK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Merck & Co., Inc. reported an operating income of 5.94B and revenue of 15.53B, resulting in an operating margin of 38.2%.
NVCR - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, NovoCure Limited reported a net income of -34.32M and revenue of 154.99M, resulting in a net margin of -22.1%.
MRK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Merck & Co., Inc. reported a net income of 5.08B and revenue of 15.53B, resulting in a net margin of 32.7%.